HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $24,205,739 | +8.4% | 633,658 | +2.4% | 0.02% | +11.8% |
| Q2 2023 | $22,330,211 | +10.4% | 619,080 | +16.6% | 0.02% | +6.2% |
| Q1 2023 | $20,232,948 | -40.6% | 530,806 | -11.4% | 0.02% | -42.9% |
| Q4 2022 | $34,074,166 | +36.8% | 598,843 | -4.9% | 0.03% | +27.3% |
| Q3 2022 | $24,901,000 | -7.5% | 629,756 | +2.9% | 0.02% | 0.0% |
| Q2 2022 | $26,918,000 | +20.5% | 611,755 | +9.2% | 0.02% | +46.7% |
| Q1 2022 | $22,343,000 | +9.0% | 560,254 | +9.9% | 0.02% | +15.4% |
| Q4 2021 | $20,504,000 | +11.9% | 509,907 | +13.2% | 0.01% | 0.0% |
| Q3 2021 | $18,331,000 | -4.2% | 450,624 | +6.9% | 0.01% | 0.0% |
| Q2 2021 | $19,138,000 | +9.3% | 421,453 | +0.3% | 0.01% | 0.0% |
| Q1 2021 | $17,517,000 | -7.9% | 420,171 | -5.6% | 0.01% | -13.3% |
| Q4 2020 | $19,016,000 | +67.1% | 445,237 | +2.8% | 0.02% | +50.0% |
| Q3 2020 | $11,382,000 | -12.8% | 433,087 | -11.1% | 0.01% | -16.7% |
| Q2 2020 | $13,058,000 | +67.8% | 487,053 | +12.6% | 0.01% | +33.3% |
| Q1 2020 | $7,781,000 | -19.1% | 432,497 | -20.3% | 0.01% | 0.0% |
| Q4 2019 | $9,618,000 | +11.0% | 542,463 | -2.9% | 0.01% | 0.0% |
| Q3 2019 | $8,661,000 | -6.8% | 558,391 | +3.3% | 0.01% | 0.0% |
| Q2 2019 | $9,291,000 | +37.3% | 540,775 | +28.7% | 0.01% | +28.6% |
| Q1 2019 | $6,767,000 | +10.9% | 420,334 | +0.8% | 0.01% | 0.0% |
| Q4 2018 | $6,101,000 | +68.2% | 416,996 | +108.9% | 0.01% | +75.0% |
| Q3 2018 | $3,627,000 | -17.1% | 199,617 | -23.1% | 0.00% | 0.0% |
| Q2 2018 | $4,377,000 | -41.6% | 259,445 | -32.1% | 0.00% | -50.0% |
| Q1 2018 | $7,490,000 | -33.1% | 382,350 | -30.9% | 0.01% | -27.3% |
| Q4 2017 | $11,204,000 | +133.8% | 552,991 | +100.4% | 0.01% | +120.0% |
| Q3 2017 | $4,793,000 | +239.0% | 275,939 | +150.2% | 0.01% | +400.0% |
| Q2 2017 | $1,414,000 | -13.8% | 110,276 | -12.9% | 0.00% | -50.0% |
| Q1 2017 | $1,641,000 | +30.4% | 126,655 | -0.5% | 0.00% | +100.0% |
| Q4 2016 | $1,258,000 | -32.1% | 127,327 | -17.0% | 0.00% | -50.0% |
| Q3 2016 | $1,853,000 | +31.6% | 153,402 | -6.0% | 0.00% | 0.0% |
| Q2 2016 | $1,408,000 | -27.3% | 163,184 | -20.2% | 0.00% | 0.0% |
| Q1 2016 | $1,938,000 | -71.8% | 204,611 | -48.4% | 0.00% | -75.0% |
| Q4 2015 | $6,876,000 | +51.8% | 396,771 | +17.7% | 0.01% | +33.3% |
| Q3 2015 | $4,529,000 | +139.0% | 337,211 | +301.9% | 0.01% | +200.0% |
| Q2 2015 | $1,895,000 | +57.7% | 83,904 | -0.3% | 0.00% | +100.0% |
| Q1 2015 | $1,202,000 | +29.1% | 84,170 | -12.7% | 0.00% | 0.0% |
| Q4 2014 | $931,000 | +11.2% | 96,434 | +4.9% | 0.00% | 0.0% |
| Q3 2014 | $837,000 | -2.3% | 91,968 | +6.0% | 0.00% | 0.0% |
| Q2 2014 | $857,000 | -7.6% | 86,727 | +18.8% | 0.00% | 0.0% |
| Q1 2014 | $927,000 | -17.7% | 72,980 | -2.9% | 0.00% | 0.0% |
| Q4 2013 | $1,126,000 | – | 75,140 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |